Nektar Therapeutics (NKTR) Net Cash Flow (2010 - 2026)

Nektar Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $134.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 2610.02% year-over-year to $134.5 million; the TTM figure through Mar 2026 stood at $110.7 million (up 1235.03% YoY), while the FY2025 annual figure was -$29.1 million, down 424.56% from the prior year.
• Net Cash Flow for Q1 2026 stood at $134.5 million, up from -$25.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $134.5 million in Q1 2026, with the low at -$29.7 million in Q4 2023.
• The 5-year median for Net Cash Flow is $2.2 million (2024), against an average of $7.3 million.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow plunged 373.69% in 2023, then jumped 2610.02% in 2026.
• Nektar Therapeutics' Net Cash Flow stood at -$17.6 million in 2022, then plunged by 68.61% to -$29.7 million in 2023, then soared by 147.59% to $14.1 million in 2024, then plunged by 283.67% to -$25.9 million in 2025, then jumped by 618.84% to $134.5 million in 2026.
• Business Quant data shows NKTR's Net Cash Flow at $134.5 million in Q1 2026, -$25.9 million in Q4 2025, and -$2.0 million in Q3 2025.